Last patient completed follow-up period in Phase II/III study of Amphera’s MesoPher cell therapy in mesothelioma
Topline results expected early Q4 2022 `S-HERTOGENBOSCH, Netherlands–(BUSINESS WIRE)–Amphera B.V., a late-stage biotechnology company developing cell therapies to treat cancer, announces that the last patient has completed the active follow-up in the Phase II/III DENIM study of MesoPher cell therapy to treat pleural mesothelioma. Ilona Enninga PhD, COO of Amphera said: “Despite the challenges experienced … [Read more…]